- Raised grant, Dec 2024
- Raised Pre-Seed round, Dec 2024
About
CLISEQ is a biotech company developing hematology clinical decision-making diagnostics. Spun out of the Weizmann Institute of Science, via its commercialization arm Yeda Research and Development Company Ltd., CLISEQ bridges world-class academic research and clinical practice to build transformative diagnostics and workflows. The company holds exclusive rights to a patented technology developed at the Weizmann Institute, which enables use of peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions such as myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration. In partnership with 10x Genomics, Inc. and the Weizmann Institute, CLISEQ is conducting an international multi-site clinical trial (PERIBLOOD) enrolling over 1,500 participants across several continents to validate the technology's clinical utility and facilitate future diagnostics workflows in hematology.
Funding history · 2 rounds · — total
Headcount over time
Q&A
- What is CLISEQ's primary focus?
- CLISEQ is a translational diagnostics company focused on advancing minimally invasive diagnostic approaches for hematologic disorders, specifically using peripheral blood single-cell RNA sequencing (scRNA-seq).
- From which institution was CLISEQ spun out?
- CLISEQ was spun out of the Weizmann Institute of Science, via its commercialization arm Yeda Research and Development Company Ltd.
- What technology does CLISEQ hold exclusive rights to?
- CLISEQ holds exclusive rights to a patented technology developed at the Weizmann Institute, which enables the use of peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions like myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration.
- What clinical trial is CLISEQ currently conducting?
- CLISEQ is conducting an international multi-site clinical trial called PERIBLOOD, which is enrolling over 1,500 participants across several continents to validate its technology's clinical utility.
- Who are CLISEQ's partners in the PERIBLOOD clinical trial?
- CLISEQ is conducting the PERIBLOOD clinical trial in partnership with 10x Genomics, Inc. and the Weizmann Institute.
- When was CLISEQ founded?
- CLISEQ was founded in January 2025.
- What is CLISEQ's primary sector?
- CLISEQ's primary sector is Health Tech & Life Sciences.
Team · 2
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cliseq.com/ |
|---|---|
| linkedin.com/company/106138084 |
Identifiers & details
| Legal name | CLISEQ Ltd. |
|---|---|
| Founded | 2025-1 |
| Employees (exact) | 1 |
Radar intelligence
Web history (Wayback)
| Domain | cliseq.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 517095618 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2025-01-08 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 2 — shares_capital (1), annual_report (1) |
| Registered address | קבוץ גלויות 89 הרצליה |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-04 | הקצאת מניות |
| 2026-03-02 | דו~ח שנתי |